# Phase 3 lung cancer trials recruiting: 40 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 40 trials in phase 3 for lung cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 3 lung cancer trials: 40 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-3/lung-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 40
- Recruiting or not yet: 40
- Read on: November 19, 2026

## Trials

The 25 newest of 40, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07947121 | A Study of Risvutatug Rezetecan in Combination With Atezolizumab in Participants With Extensive Stage Small Cell Lung Cancer... | GlaxoSmithKline | Phase 3 | Not yet recruiting | Lung Neoplasm | 700 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07947121) |
| August 20, 2026 | NCT07777822 | Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous... | Revolution Medicines, Inc. | Phase 3 | Recruiting | NSCLC, Non-small Cell Lung Cancer, Non-Small Cell Lung Cancer NSCLC, Non-Squamous Non Small Cell Lung Cancer, Lung... | 430 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07777822) |
| July 31, 2026 | NCT07738172 | Osimertinib With or Without Primary Lung Tumor Resection for EGFR-Mutant Oligometastatic Non-Small Cell Lung Cancer | National Taiwan University Hospital | Phase 3 | Recruiting | Lung Neoplasms, Non-Small Cell Lung Cancer | 154 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07738172) |
| June 4, 2026 | NCT07625644 | BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01) | SystImmune Inc. | Phase 3 | Recruiting | Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma, Sclc, SCLC,Extensive Stage, Lung... | 550 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07625644) |
| April 28, 2026 | NCT07554846 | Comparison of Perioperative Immunotherapy, Adjuvant Immunotherapy or Neoadjuvant Immunotherapy for Resectable Stage II-IIIA NSCLC | Fudan University | Phase 3 | Recruiting | Resectable Stage II-IIIa NSCLC | 759 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07554846) |
| March 30, 2026 | NCT07499674 | Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung | Vergent Bioscience, Inc. | Phase 3 | Recruiting | Lung Cancer, Lung Metastases | 132 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07499674) |
| December 17, 2025 | NCT07289646 | Functional Lung Avoidance Planning Guided by Lung Perfusion PET/CT Versus Anatomical Planning for Lung Stereotactic Body Radiotherapy | University Hospital, Brest | Phase 3 | Recruiting | Stereotactic Body Radiotherapy, 68Ga-MAA, Lung Cancer (Diagnosis) | 418 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07289646) |
| October 30, 2025 | NCT07222566 | Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants... | Pfizer | Phase 3 | Recruiting | Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma... | 1,410 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07222566) |
| September 22, 2025 | NCT07185997 | Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in... | ArriVent BioPharma, Inc. | Phase 3 | Recruiting | Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer, EGFR P-Loop and... | 480 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07185997) |
| September 4, 2025 | NCT07154368 | JYP0322 Versus Platinum Based Doublet Chemotherapy in ROS1 Positive Patients Previously Treated With ROS1-TKIs. | Guangzhou JOYO Pharma Co., Ltd | Phase 3 | Not yet recruiting | Non Small Cell Lung Cancer | 207 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07154368) |
| August 22, 2025 | NCT07135882 | Primary Radiotherapy In MEtastatic Lung Cancer | Trans Tasman Radiation Oncology Group | Phase 3 | Recruiting | Carcinoma, Non-Small-Cell Lung (NSCLC) | 420 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07135882) |
| August 17, 2025 | NCT07128199 | A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor... | Taiho Oncology, Inc. | Phase 3 | Recruiting | Lung Cancer, Adjuvant, Post-surgical, EGFR, Exon 20, Early Stage Lung Cancer, Uncommon EGFR Mutations, NSCLC, Early... | 360 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07128199) |
| August 1, 2025 | NCT07099898 | A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) \[EMBOLD SCLC-301\] | GlaxoSmithKline | Phase 3 | Recruiting | Neoplasms, Lung | 420 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07099898) |
| May 14, 2025 | NCT06970782 | Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC... | Avistone Biotechnology Co., Ltd. | Phase 3 | Not yet recruiting | Non-Small-Cell Lung Cancer | 278 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06970782) |
| May 13, 2025 | NCT06968221 | Bovine Reinforcement in Stomach, Colorectal and Lung Operation | Shanghai Cingularbio Co. Ltd | Phase 3 | Recruiting | Rectal Cancer Stage III, Lung Cancer Stage III | 172 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06968221) |
| March 18, 2025 | NCT06881784 | Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) | Revolution Medicines, Inc. | Phase 3 | Recruiting | NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma), NSCLC... | 590 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06881784) |
| January 27, 2025 | NCT06793215 | A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin... | Hoffmann-La Roche | Phase 3 | Recruiting | Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06793215) |
| January 9, 2025 | NCT06765109 | Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC | Nuvalent Inc. | Phase 3 | Recruiting | Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06765109) |
| January 3, 2025 | NCT06758401 | This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With... | Pfizer | Phase 3 | Recruiting | Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC) | 714 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06758401) |
| December 2, 2024 | NCT06712355 | Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung... | BioNTech SE | Phase 3 | Recruiting | Extensive-stage Small-cell Lung Cancer | 621 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06712355) |
| September 23, 2024 | NCT06607796 | Efficacy and Safety of Intratumoral Toluenesulfonamide (PTS) Injection in Stage IV Driver Gene-Negative NSCLC With/Without... | Sponsor not shown (see the record) | Phase 3 | Recruiting | Lung Cancer | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06607796) |
| September 19, 2024 | NCT06598527 | Stereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based... | Sponsor not shown (see the record) | Phase 3 | Recruiting | Lung Cancer (NSCLC) | 360 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06598527) |
| August 20, 2024 | NCT06563388 | Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial | Roswell Park Cancer Institute | Phase 3 | Recruiting | Oligometastasis, Lung Cancer, Colo-rectal Cancer, Prostate Cancer | 800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06563388) |
| July 15, 2024 | NCT06500481 | Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial | NRG Oncology | Phase 3 | Recruiting | Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma... | 115 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06500481) |
| July 12, 2024 | NCT06498635 | Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung... | National Cancer Institute (NCI) | Phase 3 | Recruiting | Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer... | 306 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06498635) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| National Cancer Institute (NCI) | 4 |
| Fudan University | 3 |
| [GlaxoSmithKline](https://specstream.ai/data/clinical-trials/company/glaxosmithkline) | 2 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 2 |
| [Revolution Medicines, Inc.](https://specstream.ai/data/clinical-trials/company/revolution-medicines-inc) | 2 |
| NRG Oncology | 2 |
| Nuvalent Inc. | 1 |
| National Taiwan University Hospital | 1 |
| Avistone Biotechnology Co., Ltd. | 1 |
| [Taiho Oncology, Inc.](https://specstream.ai/data/clinical-trials/company/taiho-oncology-inc) | 1 |
| Hunan Province Tumor Hospital | 1 |
| Ottawa Hospital Research Institute | 1 |
| Guangzhou JOYO Pharma Co., Ltd | 1 |
| ArriVent BioPharma, Inc. | 1 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 1 |
| Roswell Park Cancer Institute | 1 |
| [Amgen](https://specstream.ai/data/clinical-trials/company/amgen) | 1 |
| [BioNTech SE](https://specstream.ai/data/clinical-trials/company/biontech-se) | 1 |
| SystImmune Inc. | 1 |
| Sun Yat-sen University | 1 |
| Trans Tasman Radiation Oncology Group | 1 |
| Gustave Roussy, Cancer Campus, Grand Paris | 1 |
| [Hoffmann-La Roche](https://specstream.ai/data/clinical-trials/company/hoffmann-la-roche) | 1 |
| University Hospital, Brest | 1 |
| Shanghai Cingularbio Co. Ltd | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 23 |
| Australia | 16 |
| France | 15 |
| China | 15 |
| Canada | 13 |
| Italy | 13 |
| Spain | 13 |
| Germany | 12 |
| Japan | 12 |
| Poland | 12 |
| South Korea | 12 |
| Greece | 11 |
| United Kingdom | 11 |
| Taiwan | 10 |
| Brazil | 9 |
| Netherlands | 9 |
| Turkey (Türkiye) | 9 |
| Argentina | 8 |
| Belgium | 8 |
| Hungary | 8 |
| Mexico | 8 |
| Switzerland | 8 |
| Czechia | 7 |
| Hong Kong | 7 |
| Romania | 7 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Agricultural services in the United States](https://specstream.ai/data/businesses/agricultural-services/united-states)
- [Pakistani restaurants in the United States](https://specstream.ai/data/businesses/pakistani-restaurants/united-states)
- [Endodontics practices in the United States](https://specstream.ai/data/businesses/endodontics-practices/united-states)
- [Wineries in the United States](https://specstream.ai/data/businesses/wineries/united-states)
- [Ophthalmology practices in the United States](https://specstream.ai/data/businesses/ophthalmology-practices/united-states)
- [Egyptian restaurants in the United States](https://specstream.ai/data/businesses/egyptian-restaurants/united-states)
